摘要
目的探讨肿瘤切除术后肝动脉介入化疗栓塞术(TACE)治疗原发性肝癌患者的血清肿瘤标志物及生存情况。方法选取2014年1月至2016年7月间资阳市安岳县人民医院收治的行肿瘤切除术的64例原发性肝癌患者,采用随机数表法分为研究组和对照组,每组32例。两组患者均行常规肿瘤切除术,研究组患者术后2个月内行TACE治疗,比较两组患者治疗结束后血清肿瘤标志物水平,随访复发率和生存率。结果治疗后,研究组患者甲胎蛋白异质体(AFP-L3)、甲胎蛋白(AFP)、磷脂酰肌醇蛋白聚糖-3(GPC3)和高尔基体蛋白-73(GP73)含量均低于对照组,差异均有统计学意义(均P<0.05)。研究组患者1年复发率和2年复发率均低于对照组,差异均有统计学意义(均P<0.05);两组患者3年复发率比较,差异无统计学意义(P>0.05)。研究组患者1年生存率和2年生存率均高于对照组,差异均有统计学意义(均P<0.05);两组患者3年生存率比较,差异无统计学意义(P>0.05)。结论肿瘤切除术后行TACE治疗原发性肝癌患者,能有效降低患者肿瘤标志物水平,短期内有效降低复发率,提高生存率。
Objective To observe the serum tumor markers and survival in patients with primary liver cancer undergoing transcatheter arterial chemoembolization(TACE)after tumor resection.Methods Sixty-four patients with primary liver cancer who underwent tumor resection at Anyue County People’s Hospital from February 2014 to July 2016 were enrolled.The patients were divided into a study group 43 and a conventional group with 32 patients in each group.Both groups underwent conventional tumor resection.The study group underwent TACE within 2 months after the surgery.Serum tumor markers were compared between the two groups at the end of the treatment.They were followed for recurrence rate and survival rate.Results The serum alpha-fetoprotein heterogeneity(AFP-13),alpha-fetoprotein(AFP),glypican-3(GPC3)and Golgi protein 73(GP73)were significantly lower in the study group than in the conventional group(all P<0.05).The 1-year and 2-year recurrence rates were significantly lower in the study group than in the conventional group(all P<0.05).There was no significant difference in the 3-year survival between the two groups(P>0.05).The 1-year and 2-year survival rates were significantly higher in the study group than in the conventional group(all P<0.05).There was no significant difference in the 3-year survival between the two groups(P>0.05).Conclusion TACE after tumor resection can effectively reduce the tumor markers and recurrence rate and improve the survival rate.
作者
邓代安
罗坤
李祖丁
史俊华
姜永继
DENG Dai-an;LUO Kun;LI Zu-ding;SHI Jun-hua;JIANG Yong-ji(Department of Hepatobiliary Surgery,Anyue County People's Hospital,Ziyang 642350,China;Department of Intervention,Anyue County People's Hospital,Ziyang 642350,China)
出处
《中国肿瘤临床与康复》
2020年第1期62-64,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
作者简介
邓代安,男,副主任医师,主要从事肝脏肿瘤诊疗专业。
